- NOVO-B.CO -3.17% NONOF +0.06% NVO -2.86%
Novo Nordisk A/S (NYSE:NVO) is included among the 12 Best European Dividend Stocks to Buy Now.
Berenberg Lowers Novo Nordisk (NVO) Price Target to DKK 400, Maintains Buy Rating On November 14, Berenberg lowered its price target on Novo Nordisk A/S (NYSE:NVO) to DKK 400 from DKK 425 while maintaining a Buy rating on the shares, according to a report by The Fly.
Novo Nordisk A/S (NYSE:NVO) recently announced a price cut to compete with Eli Lilly (LLY) in the obesity-drug market, signaling a more aggressive effort to regain U.S. market share. For the first two months, the drugs will be available through Novo’s direct-to-consumer NovoCare portal at $349 per month, which is around 30% below current self-pay pricing. The self-pay cost for Ozempic 2mg will remain $499 per month.
In the third quarter of 2025, Novo Nordisk A/S (NYSE:NVO) reported revenue of DKK 154.94 billion, up 16.1% year-on-year. Operating profit rose 25%, while sales in the Diabetes and Obesity care segment increased 16%. Free cash flow reached DKK 33.6 billion, and the company returned DKK 35.6 billion to shareholders.
Novo Nordisk A/S (NYSE:NVO) is a global healthcare company that develops and manufactures treatments for serious chronic diseases, historically focusing on diabetes.
While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Best 52-Week Low Dividend Stocks to Invest In and 15 Best Passive Income Stocks to Buy Right Now.
Disclosure: None.
Terms and Privacy Policy Privacy Dashboard More Info